Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
February 15 2018 - 10:21AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
SEC
File Number:
005-87668
NOTIFICATION OF LATE FILING
(Check One)
: ☐ Form 10-K ☐ Form 20-F ☐
Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form
N-SAR ☐ Form N-CSR
For
Period Ended:
December 31,
2017
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
For the
Transition Period Ended: ________________________
Nothing
in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the
notification relates to a portion of the filing checked above,
identify the item(s) to which the notification
relates:
PART I -- REGISTRANT INFORMATION
Peak Pharmaceuticals, Inc.
Full
Name of Registrant
N/A
Former
Name if Applicable
14201 N. Hayden Road, Suite A-1
Address
of Principal Executive Office
(Street and Number)
Scottsdale, AZ 85260
City,
State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if
appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date;
and
|
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
PART III - NARRATIVE
State
below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period. (Attach extra
sheets if needed.)
The
compilation, dissemination and review of the information required
to be presented in the Form 10-Q for the three months ended
December 31, 2017 could not be completed and filed by the
prescribed due date without undue hardship and expense to the
registrant.
The registrant
anticipates to file such report no later than five days after its
original prescribed due date.
PART IV - OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this
notification
Neil
Reithinger
|
|
480
|
|
659-6404
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or
for such shorter period that the registrant was required to file
such report(s) been filed? If the answer is no, identify report(s).
☒ Yes ☐ No
(3) Is
it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof? ☐ Yes ☒ No
If so:
attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
Peak
Pharmaceuticals, Inc.
(Name
of Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
|
|
Date
February 15, 2018
|
By:
|
/s/
Neil
Reithinger
|
|
|
Name: Neil
Reithinger
|
|
|
Title: Chief
Executive Officer
|
|
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Historical Stock Chart
From Apr 2023 to Apr 2024